Filing Flows › AstraZeneca (AZN) › Q4 2024
AstraZeneca (AZN) Q4 2024 earnings results (fourth quarter 2024)
6-K filed Feb 6, 2025
AstraZeneca (AZN) reported revenue of $14.9B for the fourth quarter 2024 (Q4 2024), +24% from a year earlier and +10% from the quarter before. Operating margin was 13.7%, net earnings $1.5B (10.1% of revenue).
AstraZeneca, Q4 2024: revenue $14.9B (+24% year over year), operating margin 13.7%, net earnings $1.5B, operating cash flow $3.9B. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.9B | +10% | +24% |
| Gross profit | $12.2B | +16% | +25% |
| Operating profit | $2.0B | -3% | +65% |
| Net earnings | $1.5B | +5% | +56% |
| Operating cash flow | $3.9B | — | — |
| Free cash flow | $3.2B | — | — |
What changed
Revenue was $14.9B in Q4 2024, up 24% year over year and up 10% from the previous quarter. BioPharmaceuticals: CVRM was the largest line at 21% of revenue.
Gross margin was 81.7%, up 0.9 points from a year earlier. Operating profit was $2.0B, a 13.7% margin (up 3.4 points year over year). Of the extra revenue versus a year earlier, 28% reached operating profit, above the 10% margin then. Operating expenses grew 19% against revenue growth of 24%. The fastest-growing cost line was Research & development (+52%). Net earnings were $1.5B, up 57% year over year. The effective tax rate was 10.0%.
Operating cash flow was $3.9B, 261% of net earnings. Working capital and other items added $2.4B. Capital expenditures of $0.71B left free cash flow of $3.2B.
Questions
What was AstraZeneca's revenue in the fourth quarter 2024?
AstraZeneca (AZN) reported revenue of $14.9B for the fourth quarter 2024 (Q4 2024), +24% from a year earlier and +10% from the quarter before.
Was AstraZeneca profitable in the fourth quarter 2024?
Operating profit was $2.0B (13.7% of revenue) and net earnings $1.5B.
Source: AstraZeneca 6-K on SEC EDGAR.